[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Generation Next Fertility\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100594522",false,"NCT07020546","Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score","Ovarian Platelet-Rich Plasma (oPRP) Injections Improvement In IVF Patients Based On Time-Lapse Incubator Culture for Automated Tracking and AI for Embryo Quality Assessment : A Non-Randomized Propsective Self-Controlled Interventional Study","Inclusion Criteria:\n\n* No none contraindications to IVF or PRP treatment\n* Adequate ovarian reserves and AMH level\n* Willingness to undergo two IVF cycles and oPRP treatment\n\nExclusion Criteria:\n\n* Anovulation due to menopause or perimenopause\n* Any health conditions that are contraindicated for IVF or oPRP treatment",true,"FEMALE","18 Years","47 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients will have ovarian PRP treatments and embryo development will be observed using time-lapse imaging and AI software.",[27,28,29,30],"Infertility","Poor Ovarian Reserve","Embryo Growth Disorder","in Vitro Fertilization","RECRUITING","2025-07-08",{"date":34,"type":35},"2025-07-09","ACTUAL",{"date":32,"type":35},{"date":38,"type":21},"2026-08-30",{"name":40,"class":41},"Generation Next Fertility","OTHER",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":42},"100500007","NCT05790655","Ovarian PRP for Diminished Ovarian Reserve","Ovarian Platelet-Rich Plasma Injections for Diminished Ovarian Reserve Patients: A Double-Blinded Placebo-Control Trial","oPRP","Inclusion Criteria:\n\n* Clinical diagnosis of diminished ovarian reserve\n* Clinical diagnosis of poor ovarian response\n* Women age 35-42\n\nExclusion Criteria:\n\n* Clinical diagnosis of premature ovarian failure\n* Clinical diagnosis of menopause.\n* Under 35 years of age\n* Over 42 years of age","35 Years","42 Years",{"count":53,"type":21},230,[24],"This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of pregnancy and live birth compared to age-matched peers with a normal or robust ovarian reserve.",[57],"Diminished Ovarian Reserve",[59,60,61,62,63,64,65],"Ovarian Platelet Rich Plasma","DOR","Ovarian PRP","IVF","PRP","PGT-A","ICSI","2025-02-11",{"date":68,"type":35},"2025-02-13",{"date":70,"type":35},"2023-10-07",{"date":72,"type":21},"2025-12-31",{"name":40,"class":41},""]